Spectral Discrimination of Benign and Malignant Prostate Tissues––A Preliminary Report

In this preliminary report, benign (n = 8) and malignant (n = 5) prostate tissues, in vitro, have been taken through autofluorescence spectroscopy. Employing Stokes’ shift spectra and fluorescence emission spectra as tools of analysis, we were able to discriminate the two sets of tissues with sensitivity and specificity in excess of 85%. When the excised prostate chips were scanned with a spatial resolution of 1 mm, the epicenter of malignancy also could be delineated.

[1]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[2]  R. Kalaivani,et al.  Fluorescence spectra of blood components for breast cancer diagnosis. , 2008, Photomedicine and laser surgery.

[3]  Lilia Coronato Courrol,et al.  Study of Blood Porphyrin Spectral Profile for Diagnosis of Tumor Progression , 2007, Journal of Fluorescence.

[4]  V. B. Kartha,et al.  Optical diagnosis of cervical cancer by fluorescence spectroscopy technique , 2006, International journal of cancer.

[5]  Pierre Validire,et al.  Ultraviolet-induced autofluorescence characterization of normal and tumoral esophageal epithelium cells with quantitation of NAD(P)H , 2006, Photochemical and Photobiological Sciences.

[6]  Robert R. Alfano,et al.  Stokes shift emission spectroscopy of human tissue and key biomolecules , 2003 .

[7]  J Dwyer,et al.  Applications of Fourier transform infrared microspectroscopy in studies of benign prostate and prostate cancer. A pilot study , 2003, The Journal of pathology.

[8]  N Stone,et al.  The use of Raman spectroscopy to identify and grade prostatic adenocarcinoma in vitro , 2003, British Journal of Cancer.

[9]  Richard M Hoffman,et al.  Prostate-specific antigen testing accuracy in community practice , 2002, BMC family practice.

[10]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[11]  W. Catalona,et al.  The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. , 1999, Clinical chemistry.

[12]  J. García-Segura,et al.  In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology. , 1999, Magnetic resonance imaging.

[13]  G. Bottiroli,et al.  Dependence of Fibroblast Autofluorescence Properties on Normal and Transformed Conditions. Role of the Metabolic Activity , 1999, Photochemistry and photobiology.

[14]  J. K. Kim,et al.  In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external-body surface coil. , 1998, Magnetic resonance imaging.

[15]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[16]  H. Schneckenburger,et al.  Laser-induced autofluorescence for medical diagnosis , 1994, Journal of Fluorescence.

[17]  Singaravelu Ganesan,et al.  Synchronous Fluorescence Spectroscopy for the Detection and Characterization of Cervical Cancers In Vitro , 2010, Photochemistry and photobiology.

[18]  M. Feld,et al.  Quantitative characterization of biological tissue using optical spectroscopy , 2003 .

[19]  N. Ramanujam.  Fluorescence spectroscopy of neoplastic and non-neoplastic tissues. , 2000, Neoplasia.

[20]  M. Gacko.  Elastin: structure, properties and metabolism , 2000 .

[21]  D. S. Coffey,et al.  Telomerase activity: a prevalent marker of malignant human prostate tissue. , 1996, Cancer research.